tbuckley/cabot-search huggingface dataset:
Social Case Records from Psychiatric Clinics with Discussion Notes
Authors: Charlotte Towle
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neither Dead nor Sleeping.
Authors: May Wright Sewall
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intramedullary Nailing for Recent Femoral Shaft Fractures
Authors: A. E. Stevens, J. P. Turney
Journal: BMJ (1957)

CLAUDICATION BMDI1^ml Assessment of ResultsIn order to achieve a high degree of standardization a form was prepared and completed for each patient.In each case the results were assessed, after at least 18 months' treat- ment, by analys0of the information contained in these forms.The results of Treatment were classified as follows: "No benefit" means that the patient's condition had remained stationary or had become worse, as shown by a significant reduction in the walking distance before the onset of claudi- cation, progression of the skin changes, or the presence of gangrenous ulceration." Slight improvement " was considered to have taken place if the progress of the disease appeared to have been halted and if there was a slight but definite,increase in the number of yards traversed before the onset of claudication." Moderate improvement " means that after treatment the patient was able to walk at least half a mile further than had been possible before treatment.The measurement of walking distance was carried out by the patients themselves, because experience has shown that this type of patient knows fairly accurately the distance that can be walked before claudication begins.It was impressed on all these patients that they must measure this distance (at their ordinary walking speed) in paces, each pace being taken as one yard.After the trial had been in progress for about two and a half years, and all patients had received at least 18 months' treatment, it was closed and the result in each patient was assessed.Only then was I given the key to which patients had been on nicotinyl alcohol tartrate and which on placebo therapy.The results afe shown in the table.Results of Trial Treatment No. of Moderate Slight No Patients Improvement Improvement Benefit Nicotinyl alcohol tartrate ..
Effect of race on the quantity and timing of end-of-life discussions in pediatric oncology
Authors: J. N. Baker, P. S. Hinds, C. A. Zawistowski, S. Rai, Y. Ma, J. Althoff, A. Smalls, N. West, J. R. Kane
Journal: Journal of Clinical Oncology (2007)

20004 Background: Clinicians and parents report that end-of-life (EoL) care discussions and decision making are complex, difficult and affected by personal, family, and disease and treatment factors. The influence of race on EoL discussions and decision making has not been carefully examined in a large pediatric oncology study. The purpose of this study was to assess if race (white, black, Hispanic) influenced the quantity or timing of end-of-life care discussions and decisions. Methods: This abstract represents a retrospective chart review leading to the creation of an EoL database of pediatric oncology patients at St Jude Children’s Research Hospital who died during the time period of July 01, 2001 to February 28, 2005. Eligibility criteria were oncologic diagnosis, and patient age less than 21.99 years of age at the time of death. After strict application of the eligibility criteria, a total of 380 patients met study inclusion criteria. The effect of race on the quantity and timing of EoL discussions and decision making was then analyzed from the database. All extracted data were validated by a different team member as was the accuracy of all entered data. The association of race with other factors was assessed using regression analysis and chi-squared testing statistics. Results: None of the following differed by race: the total number of EoL discussions before an EoL decision was made (p=0.58); the total time from the first such discussion to a specific EoL decision (p=0.23–0.68), the total time from the first discussion to the patient’s death (p=0.105), or having a DNR in place at the time of death (p=0.55). Conclusions: In this cohort of patients from a tertiary referral center, race is not a significant factor on the quantity and timing of EoL discussions and decision making in pediatric oncology patients. [Table: see text] No significant financial relationships to disclose.
Qualitative evaluation, before meta-analysis, of the papers reporting on randomized trials testing the value of adjuvant radiotherapy to chemotherapy for small cell lung carcinoma (SCLC)
Authors: Marianne Paesmans, Sylvie Luce, Thierry Berghmans, Catherine Castaigne, Christos Sotiriou, Philippe Vermylen, Jean-Paul Sculier
Journal: European Respiratory Journal (1997)
Radiosynoviorthesis (Radiation Synovectomy)
Authors: G. Mödder
Journal: Clinical Nuclear Medicine (2008)

Radiosynoviorthesis (RSO) is a proven important instrument for local treatment of chronic inflammatory joint diseases in the context of medical and orthopaedic efforts. The term radiosynoviorthesis was created by Delbarre et al. 1968, meaning the restoration (orthesis) of the synovium by means of radionuclides. By local administration of radioactive agents an attempt is made to influence the synovial process favourably as an alternative to surgical synovectomy. In the Anglo-American literature the term"radiosynovectomy" or"radiation synovectomy" came into use.
Eculizumab Inhibits Thrombotic Microangiopathy and Improves Renal Function in Pediatric Patients with Atypical Hemolytic Uremic Syndrome: 1-Year Update
Authors: Laurence A. Greenbaum, Marc Fila, Gianluigi Ardissino, Samhar I. Al-Akash, Jonathan H Evans, Kenneth Lieberman, Silvio Maringhini, Lars Pape, Lesley Rees, Nicole C.A.J. van de Kar, Johan Vande Walle, Masayo Ogawa, Camille L. Bedrosian, Christoph Licht
Journal: Blood (2014)
Factors Influencing Short Term In Vivo Biodistribution of Human Bone Marrow Derived Mesenchymal Stem Cells (hMSCs) in a Xenogeneic Animal Model.
Authors: Charalampia Kyriakou, Neil Rabin, Amit Nathwani, Arnold Pizzey, David C. Linch, Kwee Yong
Journal: Blood (2006)
Acid Related Diseases: Biology and Treatment
Authors: George Sachs, Irvin M. Modlin
Journal: Gut (2005)

This textbook explores the history, biology, and treatment of acid related diseases, including gastric and duodenal ulcer disease, gastroesophageal reflux disease (GERD), and the role of H pylori. The text offers thorough coverage of the subject matter, with an in-depth historical and biological focus. It offers equal focus to the biology and pharmacology of acid secretion and to the specific disease states of ulcers and GERD. This edition is full of new full-color medical illustrations of all aspects of this topic.
Development of an information technology system to assist oncologists in daily clinical practice
Authors: G. Fasola, F. Puglisi, G. Aprile, O. Belvedere, A. Follador, C. Pattitoni, S. Russo, C. Sacco, L. Zanier, M. Mansutti
Journal: Journal of Clinical Oncology (2006)

16028 Background: Daily documentation and maintenance of medical record quality is a crucial issue in oncology. Computerization can offer many advantages, but needs training and motivation of operators and fitting of clinical processes and administrative rules to technological requirements. The electronic medical record (EMR) system, a software application for the entry, retrieval, and display of patients information into a digital database, could quantitatively and qualitatively improve medical recording. Methods: We developed an application system, named G2-clin, including EMR and computerized physician order-entry (CPOE). It was integrated into the hospital information system, for documentation and therapy planning to support physicians in daily clinical practice. G2-clin was developed by internal committee of oncologists, nurses and computer scientists, with an assured information technology during the learning curve and over the years. After training, staff physicians and nurses have routinely used the G2-clin starting on March 2002. Medical records collect all data concerning management of inpatient and outpatient care. Results: To date, 317 chemotherapy protocols are available in the CPOE pick list, including experimental regimens. In 2005, G2-clin registered 1550 new patients, with 7730 chemotherapy courses and was able to provide the following data: drug storage, administration and safety procedures, assessment of adverse events according CTC, specific patient safety policies, monitoring of resources and costs, data analysis for clinical research. Main benefits are improvement of the quality of patient care and safety, practice standardization, decrease in the risk of therapy ordering errors. The main drawbacks are inhibition of patient-physician interaction and visit time extension. Conclusions: According to our pilot experience, G2-clin successfully satisfied requirements of procedures standardization and allowed distribution of accurate data to all operators. Moreover it has been useful in monitoring outcomes of care, effectiveness, efficiency, adherence to clinical practice guidelines, resources and costs. No significant financial relationships to disclose.
Textbook of Secretory Diarrhea
Authors: Emanuel Lebenthal, Michael E. Duffey
Journal: Annals of Internal Medicine (1991)

cordingly, almost h~lf the text is devoted to inherited neuropathies. The authors state that they prefer to express an opinion rather than to equivocate, and in difficult areas, such as the classification of hereditary neuropathies, their views are clearly expressed without being dogmatic. In the -chapters on inherited and inflammatory-demyelinating neuropathies, the authors convey that they have grappled with problems of diagnosis and management numerous times. This acknowledgment is complemented with liberal use of illustrative case histories, which bring the text to life. Of particular interest, specific details of the authors' approaches to treating the inflammatory-demyelinating neuropathies are provided. The chapters that address neuropathies associated with systemic diseases and toxins are less informative. The difficulty partially arises from mechanically discussing the effects of a list of toxins or systemic illnesses, which is unavoidable, yet at times, the focus on pediatric aspects ofthese conditions seems lost. For example, four pages and several illustrations are devoted to a review of amyloidosis, a condition that the authors acknowledge does not occur in childhood. Some readers may think that the introductory chapters on the pathophysiologic features and investigation of neuropathy are basic. Nevertheless, these chapters containsome useful tables ofdifferential diagnosis and a helpful summary ofpublished normal values for nerve conduction studies in infants and children. The book is well produced. Illustrations are abundant, and the light and electron micrographs are ofhigh quality and have been clearly reproduced. One annoying aspect is the bibliographic citations at the end ofeach chapter that omit the titles ofarticles. Overall, despite some deficiencies, this book is concise; it effectively displays the authors' experienced perspectives on the subject and combines the scattered literature. It will be a useful addition to the libraries of neurologists and pediatricians.
Image Quality and Radiation Exposure With Prospectively ECG-Triggered Axial Scanning for Coronary CT Angiography
Authors: Jörg Hausleiter, Tanja S. Meyer, Eugenio Martuscelli, Pietro Spagnolo, Hiroaki Yamamoto, Patricia Carrascosa, Thomas Anger, Lukas Lehmkuhl, Hatem Alkadhi, Stefan Martinoff, Martin Hadamitzky, Franziska Hein, Bernhard Bischoff, Miriam Kuse, Albert Schömig, Stephan Achenbach
Journal: JACC. Cardiovascular imaging (2012)
Authors' reply to Sheehan
Authors: J. Stjernschantz Forsberg, M. G. Hansson, S. Eriksson
Journal: BMJ (2011)

Our research group has argued extensively for broad consent to future research.1 2 3 We agree with Sheehan that broad consent is informed consent and argue that implementing policies of broad, presumed, or no consent are all ways to further the good that can be achieved through biobank …
The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults
Authors: Fabienne El-Khoury, Bernard Cassou, Marie-Aline Charles, Patricia Dargent-Molina
Journal: British Journal of Sports Medicine (2013)

STUDY QUESTION Are fall prevention exercise interventions for older people living in the community effective in preventing different types of fall related injuries? SUMMARY ANSWER Exercise programmes designed to prevent falls in older adults seem also to prevent injuries caused by falls, including the most severe injuries. Such programmes also reduce the rate of falls leading to medical care.
Abstract 3444: Arachidonic 12-lipoxygenase Promotes the Development of Cardiac Fibrosis and Heart Failure via Induction of Monocyte Chemoattractant Protein-1
Authors: Yosuke Kayama
Journal: Circulation (2008)

To elucidate the molecular mechanisms of heart failure, we examined expression of 8800 genes in the heart of hypertensive heart failure model (Dahl salt-sensitive rats). DNA chip analysis revealed that 12-lipoxygenase (12-LOX) was markedly upregulated in the failing heart. 12-LOX is a key enzyme of the arachidonic cascade that metabolizes eicosanoid. Until recently, 12-LOX has been reported to play an important role in the development of atherogenesis, diabetes, and neurogenerative disease. However, the role of 12-LOX in heart failure has not been examined. To determine whether increased expression of 12-LOX causes heart failure, we established transgenic mice that overexpress 12-LOX only in cardiomyocytes. Echocardiogra-phy showed that 12-LOX transgenic mice developed systolic dysfunction from as early as 16 weeks old. Histological analysis revealed that cardiac fibrosis was increased in 12-LOX transgenic mice with advancing age, which was associated with infiltration of macrophages. Consistent with these observations, cardiac expression of monocyte chemoattractant protein-1 (MCP-1) was upregulated in 12-LOX transgenic mice compared to those of wild-type mice. In vitro experiments demonstrated that treatment with 12-hydroxy-eicosatetraenotic acid, a major metabolite of 12-LOX, increased MCP-1 expression in cardiac fibroblast and endothelial cells but not in cardiomyocytes. To determine the role of MCP-1 in the heart of 12LOX transgenic mice, we treated these mice with 7ND, an inhibitor of MCP-1, for 32 weeks. Chronic treatment with 7ND attenuated infiltration of macrophages into the myocardium and prevented systolic dysfunction and cardiac fibrosis in 12-LOX transgenic mice. Likewise, disruption of 12-LOX significantly reduced expression of MCP-1 and infiltration of macrophages in the heart, thereby inhibiting cardiac remodeling after myocardial infarction. Our in vitro and in vivo results suggest that cardiac 12-LOX is critically involved in the development of heart failure and that inhibition of 12-LOX will be a novel target for the treatment of this condition.
Phase II trial of vaccination with full length NY-ESO-1/IMX in patients with advanced malignant melanoma
Authors: T. Nicholaou, I. D. Davis, E. Marakovsky, L. Miloradovic, W. Hopkins, W. Chen, G. McArthur, L. Pan, E. W. Hoffman, L. J. Old, J. Cebon
Journal: Journal of Clinical Oncology (2006)

2571 Background: NY-ESO-1 is an immunogenic “cancer-testis” (CT) antigen, expressed in many cancers including melanoma. Iscomatrix adjuvant (IMX), a saponin-based adjuvant, was formulated with NY-ESO-1 (ESO) protein (ESO/IMX). ESO/IMX was highly immunogenic as defined by ESO specific antibody (Ab), delayed type hypersensitivity (DTH) &amp; T-cell responses in patients (pts) with resected ESO+ve cancer. Disease free survival in vaccine recipients with resected melanoma appeared longer than in controls. A prospective evaluation was subsequently undertaken to determine whether ESO/IMX could mediate antitumor responses in pts with advanced NY ESO-1+ve melanoma. Methods: 27 pts were vaccinated in a trial designed to assess objective clinical responses, safety, &amp; immunogenicity. Vaccination consisted of 100 μg ESO/IMX administered q 4 wk × 3; this cycle was repeated in pts without symptomatic progression unless they required other treatment. Pts were then eligible to continue vaccination q12 weeks so long as they were responding or stable. Results: ESO/IMX was well tolerated. 13 pts progressed when evaluated after the first cycle at week 11. No objective clinical responses were seen. Vaccine-induced antibody titers to NY-ESO-1 were comparable to those seen in the earlier minimal residual disease trial (ranging to &gt; 1: 390,000). DTH &amp; T-cell responses were less marked. This occurred despite many pts with advanced measurable disease having pre-existing spontaneous ESO immunity ( Table ). DTH responses were seen in 11 pts; 5 had pre-existing responses (2 were boosted) and 6 were induced. The DTH responses were lost by week 33. Conclusion: No objective responses were seen. Vaccine-induced immunity appeared to be attenuated in the presence of advanced metastatic disease. Ongoing laboratory studies are investigating the role of regulatory T cells in the suppression of ESO-specific immunity in these pts with a view to adopting strategies to counter regulatory responses e.g. low-dose cyclophosphamide prior to vaccination. [Table: see text] [Table: see text]
Hand-foot syndrome (HFS) in patients treated with capecitabine (CAP) and the role of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD)
Authors: V. Juneja, G. Black, J. Thornton, S. Russo, M. Johnson, R. Diasio, M. W. Saif
Journal: Journal of Clinical Oncology (2006)

8615 Background: HFS is the most common toxicity of CAP. Preclinical studies have shown that radiation (XRT) up-regulates TP, which may in turn increase efficacy of CAP. CAP is degraded by DPD, and a deficiency in this enzyme may increase toxicity of CAP. However, effect of XRT on frequency of HFS and association with TP and DPD has not been fully characterized. Methods: Toxicity data were collected from pts with LA pancreatic cancer enrolled in 3 clinical trials conducted at UAB between Apr 2001 and Jul 2005. Overall results of these trials have been reported elsewhere. Pts received XRT (50.4 Gy) with CAP (1,200–1,600 mg/m 2 BID M-F) followed CAP (2,000 mg/m 2 BID x 14 days). Pts were classified into 2 groups to evaluate HFS: CAP-XRT and CAP. Roche grading was used to assess HFS. Dose modifications were according to drug insert. Pts received prophylactic udder cream and pyridoxine. Tumor specimens were procured in 36 pts by EUS-FNA 1 wk pre- and 2 wks post XRT to evaluate TP and DPD. Age, race, sex, and PS were evaluated as prognostic factors. Results: Median duration of CAP was 6 wks (range: 3–6) for CAP-XRT and 2.5 cycles (range: 0–17) for CAP. Among 58 pts, 14 developed HFS (24%). CAP group had a higher incidence of HFS than CAP-XRT (17.2 % vs. 10.3 %; P = 0.12). Grade 2/3 HFS was observed in 15.5 % of CAP and 1.7 % of CAP-XRT (P = 0.0078). Median cumulative dose of CAP for first development of HFS was 235,000 mg/m 2 in CAP-XRT group and 3,185,000 mg/m 2 in CAP, with relative frequency of an event occurring in CAP-XRT vs. CAP of 0.59. HFS occurred at a median of 5 wks in CAP-XRT and 6 wks in CAP. Log-rank test showed neither age, sex, ECOG PS, or race was associated with development of HFS. There was no difference in tumor responses of pts with vs. without HFS. Mean tumor TP was higher among pts with vs. without HFS (275.77 vs. 215.29; P = 0.32). Mean tumor DPD was lower among pts with vs. without HFS (55.18 vs. 63.58; P = 0.49). Mean TP:DPD ratio was higher among pts with vs. without HFS (10.29 vs. 3.04; P = 0.31). Conclusions: This study suggests that incidence, severity, and time to occurrence of HFS with CAP-XRT &lt; CAP, indicating no effect of XRT. No significant association of HFS with higher tumor TP or lower tumor DPD was found. Pharmacological basis for HFS with CAP needs to be explored. [Table: see text]